Description
Lornoxicamisanon-steroidalanti-inflammatorydrug(NSAID)thatinhibitsCOX-1andCOX-2.Lornoxicamexhibitsbothanti-inflammatoryandanalgesicactivities.Invivo,lornoxicamdecreasesherpeticstromalkeratitisinducedbyherpessimplexvirusHSV-1bydecreasingactivationofNF-κBandexpressionofTNF-α.Inotheranimalmodels,lornoxicamdecreaseslevelsofprostaglandinE2(PGE2)andattenuatesFreund’sadjuvant-inducedhyperalgesia.Lornoxicamalsoexhibitssomeantioxidativeandneuroprotectiveactivities,decreasingcaspase3activityandmalondialdehydelevelsandincreasingsuperoxidedismutase(SOD)levelstopreventneuronalapoptosisinanimalmodelsofbraininjury.
References
TopcuI,VatanseverS,BayramE,etal.Theeffectsoflornoxicamonneuroprotectionfollowingdiffusetraumaticbraininjuryinrats.TurkNeurosurg.2013;23(6):764-71.PMID:24310460.
YinJ,HuangZ,XiaY,etal.Lornoxicamsuppressesrecurrentherpeticstromalkeratitisthroughdown-regulationofnuclearfactor-kappaB:anexperimentalstudyinmice.MolVis.2009Jun14;15:1252-9.PMID:19547717.
FutakiN,HaradaM,SugimotoM,etal.TheimportanceofbrainPGE2inhibitionversuspawPGE2inhibitionasamechanismfortheseparationofanalgesicandantipyreticeffectsoflornoxicaminratswithpawinflammation.JPharmPharmacol.2009May;61(5):607-14.PMID:19405999.
Radhofer-WelteS,RabassedaX.Lornoxicam,anewpotentNSAIDwithanimprovedtolerABIlityprofile.DrugsToday(Barc).2000Jan;36(1):55-76.PMID:12879104.
